Rifamycin SV MMX
Rifamycin SV MMX is a pharmaceutical product employing rifamycin SV engineered with the MMX® technology. Rifamycin SV MMX is a broad spectrum, semi-synthetic, orally non-absorbable antibiotic which may have application for the treatment of bacterial infections of the colon such as traveler’s diarrhea, infectious colitis, Clostridium difficile associated disease, diverticulitis and also as a supportive treatment of Inflammatory Bowel Diseases and Hepatic Encephalopathy.
The application of MMX® technology to Rifamycin SV allows the antibiotic to be delivered directly into the colon, potentially avoiding unwanted effects on the beneficial bacterial flora living in the upper portions of the gastro-intestinal tract.
The specific dissolution profile of Rifamycin SV MMX tablets is thought to increase the colonic disposition of the antibiotic so that an optimized intestinal concentration is achieved thus abating its systemic absorption in the small intestine. Phase III clinical trials in traveler’s diarrhea have been completed in the US and in the EU, and the NDA and MAA are currently being prepared for filing in both the US and EU, respectively. It is intended that Rifamycin SV MMX will be initially indicated for the treatment of patients with travelers’ diarrhea and subsequently moved to IBS-D. Rifamycin SV MMX is licensed to Dr. Falk Pharma for Europe and other selected territories. Dr. Falk Pharma is also conducting a phase II study in Uncomplicated Diverticulitis.
- Rifamycin SV MMX